Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
AndreyPopov/iStock via Getty Images


Biogen (NASDAQ:BIIB) and Denali Therapeutics (NASDAQ:DNLI) have commenced dosing in the phase 3 LIGHTHOUSE study examining BIIB122 for Parkinsonâs disease in those with a certain genetic mutation.
The primary endpoint is time to confirmed worsening based on the Movement Disorder Society-Sponsored Revision of the Unified Parkinsonâs Disease Rating Scale (MDS-UPDRS).

The study will enroll ~400 participants with Parkinsonâs and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene. These mutations are the most frequent ones found in Parkinson's.
The study will last 180 weeks. Participants will be randomized to receive either BIIB122 or placebo once a day.
Seeking Alpha's Quant Rating views Denali Therapeutics (DNLI) as a buy with high marks for profitability and momentum.